This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Beyond MEME, 5 ETFs to Play Latest Reddit Craze
by Sanghamitra Saha
Meme stocks are those that hog attention of retail traders due to the hype surrounding them on online forums like Reddit. These stocks and ETFs could be played in order to tap the latest Reddit frenzy.
Humana (HUM) Taps Debt Market With Senior Note Pricing
by Zacks Equity Research
Humana (HUM) exhibits monetary discretion by pricing senior secured notes to procure funds.
Why Holding Centene (CNC) in Your Portfolio is a Smart Move
by Zacks Equity Research
Banking on a robust portfolio, buyouts and alliances plus contract wins, Centene (CNC) holds prospects to reap benefits for investors.
Why Holding Anthem (ANTM) in Your Portfolio is a Prudent Move
by Zacks Equity Research
Riding high on better membership, a robust portfolio and operational excellence, Anthem (ANTM) holds potential to reap benefits for investors.
Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?
by Zacks Equity Research
Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).
HCA Healthcare (HCA) Up 43.1% in a Year: Is More Upside Left?
by Zacks Equity Research
Growing revenues, numerous acquisitions and a sturdy financial standing continue to drive HCA Healthcare (HCA).
Tenet Healthcare (THC) Up 55% in a Year: Is More Upside Left?
by Zacks Equity Research
Growing revenues, strong performances exhibited by segments, numerous acquisitions and sturdy financial standing continue to drive Tenet Healthcare (THC).
Anthem (ANTM) to be Renamed as Elevance Health for Rebranding
by Zacks Equity Research
Anthem (ANTM) intends to rename itself as Elevance Health to solidify its position in the market that goes beyond traditional insurance products.
Should Value Investors Consider MEDNAX (MD) Stock Now?
by Zacks Equity Research
Is MEDNAX (MD) a great pick from the value investor's perspective right now? Read on to know more.
4 Stocks to Watch From the Flourishing Hospital Industry
by Kaibalya Pravo Dey
Rising patient volumes and the growing aging population are driving Zacks Medical-Hospital industry players' profits. HCA Healthcare, Universal Health, Tenet Healthcare and Mednax are poised to benefit from improving operating efficiency.
Here's How Mednax (MD) Can Gain By Adopting the Pediatrix Brand
by Zacks Equity Research
Mednax (MD) bringing some of its operations under the Pediatrix brand is expected to collectively promote its wide range of healthcare services.
Tenet Healthcare (THC) Drops Plans to Spin Off Conifer Segment
by Zacks Equity Research
Tenet Healthcare (THC) aborts its Conifer spin-off plan based on its solid business opportunities and strong pipeline prospects. It also reaffirmed its 2022 guidance.
Acadia Healthcare (ACHC) Q4 Earnings Miss on High Operating Costs
by Zacks Equity Research
Acadia Healthcare (ACHC) anticipates earnings per share within 62-66 cents for the March quarter of 2022.
Universal Health (UHS) Q4 Earnings Beat on Higher Patient Days
by Zacks Equity Research
Universal Health Services (UHS) expects capital expenditures for 2022 to increase from the 2021 level to the range of $950-$1,100 million.
Mednax's (MD) Q4 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
Mednax's (MD) Q4 results improve on better revenues and expanded patient volumes.
Mednax (MD) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 18.18% and 3.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Community Health Systems (CYH) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Community Health Systems (CYH) delivered earnings and revenue surprises of 130% and 0.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Mednax (MD) Pursues $1.1B Transactions to Reduce Debt Burden
by Zacks Equity Research
Mednax (MD) issues senior notes, and a new revolving credit facility coupled with a term loan remains in place, which is aimed at reducing MD's debt level and associated interest expenses.
Mednax (MD) to Post Q4 Earnings: Here's What You Need to Know
by Zacks Equity Research
Mednax's (MD) fourth-quarter results are likely to reflect growth in same-unit revenues and NICU days.
Mednax (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mednax (MD) Buys Night Lite Pediatrics to Boost Portfolio
by Zacks Equity Research
Mednax (MD) purchases Night Lite Pediatrics, LLC in Orlando to enhance its pediatric business line.
Here's Why Seasoned Investors are Retaining Mednax (MD)
by Zacks Equity Research
Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.
The Zacks Analyst Blog Highlights: Community Health Systems, Mednax, HCA Healthcare and Tenet Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Community Health Systems, Mednax, HCA Healthcare and Tenet Healthcare
3 Hospital Stocks That Crushed S&P 500 YTD, Set to Rise Further
by Srijita Guha
High patient volumes, mergers and buyouts, and demand for virtual health services are likely to help hospital companies like THC, HCA and CYH.
MEDNAX's (MD) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
MEDNAX's (MD) third-quarter results reflect growing revenues driven by rising patient volumes, partly offset by higher general and administrative expenses.